BridgeBio Oncology Therapeutics, Inc. (BBOT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BridgeBio Oncology Therapeutics, Inc. (BBOT) has a cash flow conversion efficiency ratio of -0.096x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-35.92 Million) by net assets ($372.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BridgeBio Oncology Therapeutics, Inc. (BBOT) market capitalisation for the company's overall valuation and market capitalisation.
BridgeBio Oncology Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how BridgeBio Oncology Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
BridgeBio Oncology Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BridgeBio Oncology Therapeutics, Inc. ranked by their cash flow conversion efficiency. Explore BBOT cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Indo Tech Transformers Limited
NSE:INDOTECH
|
0.000x |
|
Berto Acquisition Corp. Ordinary Shares
NASDAQ:TACO
|
0.000x |
|
Cheng Mei Materials Technology Corp
TW:4960
|
0.050x |
|
HELLOFRESH UNSP.ADS/025
F:HFG0
|
0.203x |
|
Moura Dubeux Engenharia S.A
SA:MDNE3
|
-0.029x |
|
GDI Integrated
TO:GDI
|
0.066x |
|
Hunan Creator Information Technologies Co Ltd Class A
SHE:300730
|
-0.006x |
|
Y mAbs Therapeutics
NASDAQ:YMAB
|
0.019x |
Annual Cash Flow Conversion Efficiency for BridgeBio Oncology Therapeutics, Inc. (2023–2025)
The table below shows the annual cash flow conversion efficiency of BridgeBio Oncology Therapeutics, Inc. from 2023 to 2025. View latest BridgeBio Oncology Therapeutics, Inc. stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $411.10 Million | $-113.89 Million | -0.277x | -6745.05% |
| 2024-12-31 | $188.72 Million | $-763.82K | -0.004x | -100.00% |
| 2023-12-31 | $-63.57K | $-52.08 Million | 819.252x | -- |
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients… Read more